600721 百花医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)3.3015.6621.889-5.1579.200
总资产报酬率 ROA (%)2.2843.8111.257-3.5056.114
投入资产回报率 ROIC (%)2.6774.5871.551-4.2877.646

边际利润分析
销售毛利率 (%)49.40051.18849.03739.91840.039
营业利润率 (%)15.1669.6014.862-8.78622.584
息税前利润/营业总收入 (%)14.8399.1944.229-9.25822.061
净利润/营业总收入 (%)12.61010.7533.513-9.92821.281

收益指标分析
经营活动净收益/利润总额(%)167.174251.468413.100-82.17354.055
价值变动净收益/利润总额(%)5.1289.14211.860-0.0340.707
营业外收支净额/利润总额(%)-0.323-0.464-8.9464.282-2.197

偿债能力分析
流动比率 (X)2.0261.8871.8311.7491.844
速动比率 (X)1.7221.5641.4261.2321.079
资产负债率 (%)29.66131.93833.46433.41030.139
带息债务/全部投入资本 (%)13.09014.76712.72811.98410.955
股东权益/带息债务 (%)625.881543.623642.967687.595765.453
股东权益/负债合计 (%)237.137213.107198.825199.308230.123
利息保障倍数 (X)-53.184-25.331-18.028117.429-581.341

营运能力分析
应收账款周转天数 (天)83.63445.45517.45119.09225.494
存货周转天数 (天)163.660214.662262.317294.099408.022